Interview with Dejan Jovanovic, General manager, Astellas Russia
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
Address: 109147, Moscow,Russia
Tel: +7 (495) 737 0755
Web: http://www.astellas.com/worldwide.html
Pharma (the Netherlands), its Representative office was opened in Moscow in 1994. Yamanouchi Company was found on the basis of Brocades Company. In 2005 a new multinational company Astellas was found as a result of two Japanese companies’ merger – Fujisawa and Yamanouchi. Main Astellas goal is to improve people’s lives and give them hope for the future with innovative pharmaceutical products and also become a Global Category Leader in chosen therapy areas.
Astellas is among top 20 companies of the world successfully managing its business in different countries such as Japan, North America (the USA and Canada), Europe and Asia. Headcount of Astellas worldwide is more than 17 thousand people.
Russian affiliate is related to European branch – Astellas Pharma Europe. Astellas Russia is responsible for business in Russia, the Ukraine, Belarus, Kazakhstan, Azerbaijan, Armenia, Moldova, Georgia, Kirgizia, Turkmenistan, Tajikistan, Uzbekistan and Mongolia.
Astellas has 4 global corporate principals which are called STAR: Success driven, Team oriented, Adoptable and Respectful.
Russian affiliate headcount is continuingly growing. They are young and vigorous professionals who can achieve their ambitious goals. Astellas aim is to become an Employer of Choice. That is why it is trying to improve HR policy, social package and team spirit.
Infectives, Transplantation, Oncology, Pail Management and others. Astellas brand products are: Omnic, Prograf, Flemoxin Solutab, Wilprafen Solutab, Unidox Solutab, Pimafucin, Zineryt, DeNol, Phosphalugel and others.
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here